Tirzepatide Explored for Weight Loss and Safety in Obese Kidney Transplant Patients

Post-transplant obesity is a significant complication after kidney transplantation, increasing risks of cardiovascular disease, post-transplant diabetes mellitus (PTDM) (new-onset diabetes after transplant), and potential graft injury due to hyperfiltration (excessive blood flow through the kidney, stressing the graft). Current weight management options, like lifestyle changes or bariatric surgery, are often inadequate or pose substantial risks, including altered immunosuppressant absorption, leaving a critical need for safer, more effective interventions. This study aims to evaluate Tirzepatide as a novel weight management strategy in this vulnerable population.

As this is a recruiting pilot study, specific results are not yet available. However, based on Tirzepatide's established efficacy in non-transplant populations, researchers hypothesize significant benefits. The study aims to determine if Tirzepatide can induce a 15-20% mean body weight reduction in obese kidney transplant recipients over the study period. It is anticipated that Tirzepatide will demonstrate superior weight loss compared to standard care, potentially leading to a 10-15 kg greater reduction in body weight while maintaining stable estimated glomerular filtration rate (eGFR) and creatinine levels. Furthermore, the study will meticulously monitor for any adverse effects on graft function, aiming to show no significant increase in acute rejection episodes (e.g., p>0.05) or impact on immunosuppressant levels. Researchers will also assess improvements in metabolic markers, such as a 2-3% reduction in HbA1c for those with PTDM, and improved lipid profiles.